Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11

21 juin 2018

03:30
Unilateral MRI-guided Focused Ultrasound Thalamotomy for Treatment-resistant Essential Tremor Recognised by National Institute for Health and Care Excellence  INSIGHTEC®, a global medical technology innovator of incisionless surgery, announced...

03:00
Steba Biotech, une société privée de biotechnologie spécialisée dans le développement de thérapies et de systèmes photodynamiques innovants et mini-invasifs dans le traitement des cancers, a annoncé aujourd'hui la publication dans le "Journal of...

02:17
The previously announced breakthrough update to Nevisense, SciBase device for the early detection of melanoma, has now been released. "To be accepted by an even broader customer group, we needed to improve the ease of use of Nevisense and make it...

02:14
Alligator Bioscience , a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present additional preclinical data for the drug candidate ATOR-1017 at the 3rd Annual World Preclinical Congress in...


20 juin 2018

11:09
The diaTribe Foundation announced the release of The Anthology of Bright Spots in Type 2 Diabetes and Prediabetes, a first-of-its-kind resource that describes successful prevention, treatment, and management programs in prediabetes and type 2...

10:20
AIVITA Biomedical, a biotech company specializing in innovative stem cell applications, announced today the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase II clinical trial investigating...

09:30
Taiho Oncology, Inc. today announced a Phase I study to examine the efficacy of TAS-120, an investigational irreversible pan-fibroblast growth factor receptor (FGFR) inhibitor as a potential treatment for patients with advanced solid tumors,...

09:00
SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, announced the first patient has been enrolled in REN026, the Phase 1b clinical trial of Pexa-Vec...

08:30
NuVasive, Inc. , the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the results of the study "Early Outcomes of Anterior Cervical Discectomy...

08:00
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today announced it received clearance from the Food and Drug Administration to initiate the first Phase 1 clinical trial of its...

07:30
Neovasc Inc. ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducertm (the "Reducer"), a...

07:07
CStone Pharmaceuticals (CStone) today announced the initiation of a Phase I clinical trial in Australia for CS3006, a highly selective, proprietary small molecule inhibitor of mitogen-activated protein kinase kinase (MEK). The first patient enrolled...

03:00
Steba Biotech, a privately-owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announced that the Journal of Urology has published 4-year follow up...


19 juin 2018

16:02
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active...

12:54
LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce the publication of recommendations that will create more opportunities for patients to participate in potentially lifesaving clinical...

10:45
StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care, today announced that the first patient has been enrolled in the company sponsored clinical trial assessing the safety and efficacy of Revita full...

10:40
At last week's EHA meeting, Tolero Pharmaceuticals, Inc. presented positive data in patients treated with alvocidib, a cyclin-dependent kinase (CDK) inhibitor class drug, in combination with standard of care for acute myeloid leukemia: Zeidner, et...

09:52
June 19, 2018, Luye Pharma Group announced that clinical applications of the company's new compound candidate, extended release tablets (''LY03012''), a China Class 1.1 new chemical drug, have been formally accepted by the China Food and Drug...

09:42
Arthrosurface, Inc. announced today that midterm clinical results reconfirmed joint preservation in patellofemoral (PF) surgery with the PF Wavetm Implant System. 5-year results presented by Dr. Jonas Pogorzelski at the recent ESSKA Congress in...

09:25
Artemis Therapeutics, Inc. , ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, today announced that data on its lead product candidate...

09:04
Seattle Children's has opened a pioneering chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory HER2-positive central nervous system (CNS) tumors where CAR T cells will be delivered...

09:00
Beckman Coulter announced today the positive results of a clinical trial suggesting that blood tests may offer key benefits in the initial screening for obstructive sleep apnea. The study, which involved 264 male adult patients from six institutions,...

08:48
Heel Defender Orthotic Insoles have been selected for use in an important clinical trial of a new treatment for Achilles Tendonitis.  Defender Operations is pleased to announce that its flagship product, Heel Defender Comfort Orthotic Insoles, are...

08:03
Natera, Inc., , a global leader in cell-free DNA testing, today announced a research collaboration with the Institut Jules Bordet, an internationally renowned multidisciplinary cancer reference center in Belgium, using the company's Signateratm...

08:00
Today Amgen Canada announced that Health Canada has now indicated Repatha as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy), to reduce...

08:00
Greenphire, the global leader in financial software for clinical trials, today announced it has partnered with Lyft, to deliver a seamless experience for site coordinators to book a ride and execute a reimbursement or stipend for clinical trial...

08:00
Amgen Canada a annoncé aujourd'hui que Santé Canada avait homologué l'indication de Repatha comme traitement d'appoint au régime alimentaire et au traitement de référence (y compris au traitement d'intensité modérée ou élevée par une...

06:00
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or...

06:00
Kallyope Inc. and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an...

00:49
Carmentix Pte. Ltd. is proud to announce a research collaboration with The University of Melbourne (UoM), The Chinese University Hong Kong (CUHK) and The Henan Province People's Hospital for a clinical Preterm Birth study to validate Carmentix's...


18 juin 2018

15:32
Ce communiqué n'est pas destiné aux médias basés aux États-Unis ou au Royaume-Uni L'analyse post-hoc de l'étude CLARITY suggère une efficacité clinique et de l'imagerie par résonance magnétique constante dans des sous-groupes de plus jeunes adultes...

12:00
Research led by Oleg Batishchev and conducted jointly by scientists from NUST MISIS, the A.N. Frumkin Institute of Physical Chemistry & Electrochemistry (Russian Academy of Sciences), and the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry...

10:02
Elekta (EKTA-B.ST) earlier today announced (14:15 CET) that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark, clearing the technology for commercial sales and clinical use in Europe. To view the Multimedia...

09:00
Arcuro Medical Ltd. ("Arcuro"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) , announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its SuperBalltm meniscus...

09:00
The Cefaly® ACUTE medical device, recently cleared by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine, is the subject of a large phase 3 clinical trial in the United States that is progressing rapidly. Previous pilot...

08:40
Hygieia, a digital insulin enhancement company dedicated to making insulin therapy easier for everyone involved, announced today that the company will present clinical trial data evaluating the use of its d-Nav® Insulin Guidance Service among people...

08:30
Champions Oncology, Inc. , engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National...

08:00
Essential Medical, Inc., a private medical device company focused on innovative solutions for large bore vascular closure, today announced that the results from the SAFE MANTA IDE clinical trial will be presented at the Transcatheter Valve Therapies...

08:00
Array BioPharma Inc. announced that it will present updated safety and efficacy results, including overall survival (OS) data, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF...

08:00
Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. , today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA)...

08:00
Leviticus Cardio, inventor of wireless technology for certain medical devices, announces the successful animal implantation of the world's first Hybrid Wireless Fully Implanted Ventricular Assisted System or "Hybrid FILVAS." The new cardio device,...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that new data presented at the 23rd Annual Congress of the European Hematology Association (EHA), held in Stockholm, Sweden, shows that...

07:00
Protagonist Therapeutics, Inc. today announced that results of a Phase 1 study in healthy volunteers and supportive pre-clinical data for the Company's novel injectable hepcidin mimetic, PTG-300, were the subject of oral presentations on June 16,...

06:30
Mallinckrodt plc , a leading global specialty pharmaceutical company, recently reported preliminary interim data from ongoing H.P. Acthar® Gel (repository corticotropin injection) studies, including the company's Phase 4 Rheumatoid Arthritis (RA)...

06:00
Not intended for U.S or U.K based media Post-hoc analysis of CLARITY study suggests consistent clinical and Magnetic Resonance Imaging efficacy in subgroups of both younger and older adults treated with MAVENCLAD (cladribine tablets)  Using an...

02:45
Medivir AB today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the design of the planned pivotal phase III clinical study of remetinostat for the treatment...

02:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that positive results from the pivotal QuANTUM-R phase 3 study of single agent quizartinib were presented today as a late-breaking oral presentation in the plenary program at the...


17 juin 2018

20:00
Each year, more than one million Americans are diagnosed with adult-onset diabetes mellitus, also known as type 2 diabetes. The new diagnosis comes with a long list of potential complications: high blood pressure, nerve damage, kidney disease,...

06:00
Aprea Therapeutics presented results at the 2018 EHA Annual Meeting from its Phase Ib/II clinical study in MDS. The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS....


16 juin 2018

13:36
PTC Therapeutics, Inc. today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy (SMA), at the 22nd Annual SMA Researcher...

1 2 3 4 5 6 7 8 9 10 11